ACTRIMS 2024: Cladribine Tablets Demonstrate Continued Efficacy at Three Years in Highly Active Relapsing MS
High rate of participants had no evidence of disease activity outcomes after three years of treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.